SANDOZ

📅 Upcoming

🕒 Recent(90d)

News

• Austria’s new growth fund could further bolster its dynamic biotech innovation economy
  The national growth vehicle isn’t biotech‑dedicated, but channeling capital toward life sciences would amplify Austria’s strong research hubs, nondilutive funding landscape and reputation as a cham…
  biospace · 4d ago
• STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
  In today's Pharmalittle newsletter, a Medicare pilot and orphan drugs, Pfizer cutbacks, and more.
  stat · 9d ago
• STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
  Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug
  stat · 10d ago
• STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
  A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
  stat · 11d ago
• STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
  The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.
  stat · 11d ago
• Michigan reports the first 2 U.S. deaths related to a diarrhea-causing parasite
  Two people have died in the cyclospora outbreak in Michigan in the first confirmed deaths in the U.S. related to the microscopic parasite, state health officials announced.
  stat · 11d ago
• STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments
  Medicare is removing flexibilities that have allowed "breakthrough" medical devices to leapfrog qualifications for extra payments.
  stat · 11d ago
• Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing case
  ☢️ Curium spends $8B for Lantheus: Curium is buying fellow radiopharma company Lantheus for $102.5 per share. Lantheus shareholders may receive $12 more per share if certain targets are achieved ...
  endpoints · 11d ago
• STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
  AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of ​the world's biggest drugmakers
  stat · 11d ago
• STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
  Sandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.
  stat · 12d ago